Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug;163(7):1423-31.
doi: 10.1111/j.1476-5381.2011.01352.x.

The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications

George Kunos  1 , Joseph Tam
Affiliations
Review

The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications

George Kunos et al. Br J Pharmacol. 2011 Aug.

Abstract

In this review, we consider the role of endocannabinoids and cannabinoid-1 (CB(1)) cannabinoid receptors in metabolic regulation and as mediators of the thrifty phenotype that underlies the metabolic syndrome. We survey the actions of endocannabinoids on food intake and body weight, as well as on the metabolic complications of visceral obesity, including fatty liver, insulin resistance and dyslipidemias. Special emphasis is placed on weighing the relative importance of CB(1) receptors located in peripheral tissues versus the central nervous system in mediating the metabolic effects of endocannabinoids. Finally, we review recent observations that indicate that peripherally restricted CB(1) receptor antagonists retain efficacy in reducing weight and improving metabolic abnormalities in mouse models of obesity without causing behavioural effects predictive of neuropsychiatric side effects in humans.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Therapeutically relevant effects of blockade of peripheral cannabinoid 1 (CB1) receptors in visceral obesity/metabolic syndrome. BBB, blood/brain barrier; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglyceride.
See this image and copyright information in PMC

References

    1. Alexander SP, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol. 2008;153(Suppl 2):S1–209. - PMC - PubMed
    1. Bellocchio L, Lafenetre P, Cannich A, Cota D, Puente N, Grandes P, et al. Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci. 2010;13:281–283. - PubMed
    1. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003;63:908–914. - PubMed
    1. Beyer CE, Dwyer JM, Piesla MJ, Platt BJ, Shen R, Rahman Z, et al. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis. 2010;39:148–155. - PubMed
    1. Bilkei-Gorzo A, Drews E, Albayram O, Piyanova A, Gaffal E, Tueting T, et al. Early onset of aging-like changes is restricted to cognitive abilities and skin structure in Cnr1(−/−) mice. Neurobiol Aging. 2010 DOI: 10.1016/j.neurobiolaging.2010.07.009. - DOI - PubMed

Publication types

MeSH terms

Substances